Company intelligence / Profile preview

PMV Pharmaceuticals, Inc.

Princeton, New Jersey, United Statespmvpharma.com ↗

Ownership: Public · PMVP
Development stage: Phase 2

Overview

PMV's lead candidate rezatapopt (PC14586) is in Phase 2 pivotal trials for patients with TP53 Y220C and KRAS wild-type advanced solid tumors. Enrollment is on track with more than 90% of sites activated across the U.S., Europe, U.K., and Asia-Pacific. Interim analysis data is expected mid-2025. A Phase 1b study evaluating rezatapopt monotherapy and in combination with azacitidine in patients with relapsed/refractory AML/MDS harboring a TP53 Y220C mutation has also commenced enrollment.[5][6]

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

4 assets

rezatapopt

3 more assets in the full pipeline.

Request access →

Partnerships

Merck & Co. (for combination with Keytruda)Foundation MedicineMD Anderson Cancer Center

Beyond the preview

Go deeper on PMV Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PMV Pharmaceuticals, Inc..

Explore the full profile